Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
Status:
Completed
Trial end date:
2021-02-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of filgotinib as compared to
placebo in establishing combined fistula response at Week 24. Participants will have the
option to enter a separate long-term extension study if they meet eligibility requirements.